Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX

NCT02020369 is registered in ClinicalTrials.gov with rEVO Biologics as lead sponsor.

NCT NCT02020369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02020369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Lead sponsor
rEVO Biologics
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2014
Completion date
August 31, 2015
Enrollment
27 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a with inhibitors, hemophilia b with inhibitors